Skip to main content

Share story

Science

Heidelberg-led studies map malaria parasite nucleus tethers and nuclear multiplication

Heidelberg-led studies map malaria parasite nucleus tethers and nuclear multiplication Image: Primary
Two studies involving Heidelberg University's Faculty of Medicine, Harvard Medical School and the German Cancer Research Center examine how malaria parasites multiply by first amplifying genetic material many times before producing large numbers of daughter parasites, phys.org reported. In The EMBO Journal, teams led with Friedrich Frischknecht of Heidelberg and Jeffrey Dvorin of Boston Children's Hospital and Harvard Medical School identified two proteins that form a molecular tether linking each new nucleus to the tip of a budding daughter parasite. Without the tether, daughter formation inside blood cells was severely impaired. Genetically modified parasites lacking one tether component still replicated genomes but could not produce viable progeny, and sporozoite formation in mosquitoes was almost completely abolished. Frischknecht said that without the connecting structure, daughter formation collapses because developing parasites cannot pull the nucleus inside or correctly orient structures needed for host-cell invasion. A second study in Nature Communications, with DKFZ involvement among the collaborations named in the writeup, addresses competitive resource allocation that drives asynchronous and rapid nuclear multiplication in the parasite. Phys.org said the combined insights show how the parasite uses limited resources inside infected blood cells and open perspectives for future antimalarial drug development. Papers cited include Buyuan He et al. in The EMBO Journal (DOI 10.1038/s44318-026-00836-7) and Patrick Binder et al. in Nature Communications (DOI 10.1038/s41467-026-75378-x). Antimalarial discovery programs gain two concrete cellular mechanisms, nucleus-apical tethering and resource-driven nuclear multiplication, as potential intervention points.
Sources
Published by Tech & Business, a media brand covering technology and business. This story was sourced from phys.org and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
AI Science
AI Science

Insilico says AI-discovered Rentosertib has entered Phase III trials

Insilico Medicine says Rentosertib, its generative AI-discovered drug candidate also known as ISM001-055, has entered Phase III clinical trials for idiopathic pulmonary fibrosis. The company described the clinical advance in an announcement carried by News-Medical.Net.

Infrastructure Science
Infrastructure Science

Quilty Space projects shortfall of about 150 launches through 2030

The world outside China faces a shortfall of about 150 rocket launches through 2030 against demand from satellite operators and civil space agencies, analytics firm Quilty Space estimates in a new report.